GLP+ supplies research-grade Retatrutide across Indonesia. The newest generation weight management peptide, activating three incretin receptors. Available in 5mg, 10mg or 30mg, vial or pen. Nationwide delivery via WhatsApp.
Three sizes, two formats, six SKUs in stock. All prices in IDR, no hidden fees.
The newest weight management peptide, activating three metabolic receptors instead of one or two.
Retatrutide is a triple-agonist research peptide that activates the GLP-1, GIP and Glucagon receptors simultaneously. By engaging three metabolic pathways, it represents the most aggressive evolution of the GLP-1 weight management family, going beyond Semaglutide (single receptor) and Tirzepatide (dual receptor).
In published research, Retatrutide has produced some of the largest body-composition changes ever recorded for an incretin peptide, which is why it has rapidly become the most-requested compound in our Bali catalog. It is also the only weight management peptide we offer in three different vial sizes, giving researchers the flexibility to dose for short-term pilots (5mg) or long-running protocols (30mg).
We stock Retatrutide in 5mg, 10mg and 30mg vials, plus matching pre-filled pens in the same three sizes. The vial is the most cost-effective format and offers the most dosing flexibility. The pen is pre-loaded with bacteriostatic peptide and clicks to a set dose with no reconstitution required. Both formats are tested independently at 99%+ purity.
GLP+ has the deepest Retatrutide catalog in Indonesia, with all three sizes stocked across both formats. Customer reviews on Google highlight Retatrutide specifically (5.0 stars from 60 verified reviews at our Canggu flagship in Bali, operated by parent brand Peptide+). Pricing is in Indonesian Rupiah with no hidden fees.
The science, translated for non-researchers.
Retatrutide is a synthetic peptide that mimics three different hormones your gut already makes after a meal: GLP-1, GIP and Glucagon. Together these three hormones control hunger, how your body handles sugar and fat, and how much energy you burn at rest. Most weight management peptides only mimic one or two of them. Retatrutide is the first to mimic all three at once, which is why its published weight reduction numbers are the largest in the category.
Slows how fast food leaves your stomach and signals fullness to your brain. You feel full sooner after a meal, and stay full longer.
In practice: smaller portions feel normal, snacking urges fade, you stop thinking about food between meals.
Improves your insulin response so the sugar and fat from what you eat is handled more efficiently instead of being stored.
In practice: better blood-sugar stability after meals, less of the energy you eat ends up as new body fat.
Increases your body's energy expenditure even when you are not moving. This is the metabolic boost that single and dual GLP agonists do not have.
In practice: your resting calorie burn goes up. Combined with eating less, this drives the larger weight reductions seen in studies.
Real numbers from peer-reviewed publications and official trial announcements.
All claims above are from peer-reviewed publications or official manufacturer trial announcements. Retatrutide is supplied by GLP+ as a research peptide for in-vitro and laboratory use only. We do not provide medical advice, dosing guidance, or treatment recommendations. For citations and published dosing protocols, see our researcher resources page.
Retatrutide is a triple-agonist research peptide that activates the GLP-1, GIP and Glucagon receptors. It is the newest and most aggressive of the three weight management GLPs we carry, with published research showing some of the largest body-composition changes ever recorded for an incretin peptide.
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP and Glucagon). The added Glucagon agonism is the unique feature of Retatrutide and the reason researchers often choose it after exhausting single or dual-receptor protocols.
Most researchers start with the 10mg vial: it has the best price per mg and enough peptide for several weeks of standard dosing protocols. The 5mg is best for short pilot studies or first-time research. The 30mg is typically ordered for long-running protocols or research groups.
Vials require reconstitution with bacteriostatic water (which we can include with your order) and offer flexible dosing in any increment. Pens are pre-filled, click-to-dose, no mixing required, and easier to travel with. Pens cost roughly IDR 800k-1.1m more per size than the matching vial.
All Retatrutide ships in temperature-controlled packaging with cold-chain protection, important in the Indonesian climate. Pens and vials arrive intact and ready to refrigerate. Same-day dispatch for orders placed before 5 PM.
Yes. All Retatrutide sold by GLP+ is intended for research purposes only. We do not provide medical advice, dosing guidance, or treatment recommendations.
Retatrutide is the most aggressive triple-receptor option. Some researchers prefer to start lighter.
The original GLP-1 weight management peptide. Longest research history, often used as the baseline before stepping up.
Learn about Semaglutide →The dual-action middle option. Stronger metabolic response than Semaglutide, longer research history than Retatrutide.
Learn about Tirzepatide →Six SKUs in stock, vial or pen, all sizes. Same-day responses on WhatsApp.
Message Us on WhatsApp